FR2774591B1 - Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie - Google Patents

Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie

Info

Publication number
FR2774591B1
FR2774591B1 FR9801709A FR9801709A FR2774591B1 FR 2774591 B1 FR2774591 B1 FR 2774591B1 FR 9801709 A FR9801709 A FR 9801709A FR 9801709 A FR9801709 A FR 9801709A FR 2774591 B1 FR2774591 B1 FR 2774591B1
Authority
FR
France
Prior art keywords
fibrate
metformin
medicines
association
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9801709A
Other languages
English (en)
Other versions
FR2774591A1 (fr
Inventor
Yves Bonhomme
Philippe Briet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
LIPHA SAS
LIPHA Liyonnaise Industrielle Pharmaceutique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9801709A priority Critical patent/FR2774591B1/fr
Application filed by LIPHA SAS, LIPHA Liyonnaise Industrielle Pharmaceutique filed Critical LIPHA SAS
Priority to BR9907866A priority patent/BRPI9907866B8/pt
Priority to IDW20001765A priority patent/ID26254A/id
Priority to CZ20002828A priority patent/CZ290101B6/cs
Priority to EP99910169A priority patent/EP1054665B1/fr
Priority to HK01105732.1A priority patent/HK1034913B/xx
Priority to PL342665A priority patent/PL196874B1/pl
Priority to SI9930017T priority patent/SI1054665T1/xx
Priority to SK1156-2000A priority patent/SK283212B6/sk
Priority to UA2000095172A priority patent/UA70315C2/uk
Priority to DE69900249T priority patent/DE69900249T2/de
Priority to PT81108560T priority patent/PT1054665E/pt
Priority to HU0100801A priority patent/HU224619B1/hu
Priority to DK99910169T priority patent/DK1054665T3/da
Priority to RU2000123567/14A priority patent/RU2207850C2/ru
Priority to JP2000531156A priority patent/JP4767411B2/ja
Priority to US09/601,618 priority patent/US6372790B1/en
Priority to PCT/EP1999/000614 priority patent/WO1999040904A2/fr
Priority to AU29233/99A priority patent/AU746821B2/en
Priority to ES99910169T priority patent/ES2162517T3/es
Priority to AT99910169T priority patent/ATE204754T1/de
Priority to CA002320039A priority patent/CA2320039C/fr
Priority to KR1020007008836A priority patent/KR100567608B1/ko
Priority to CNB998029041A priority patent/CN1151785C/zh
Priority to MYPI99000445A priority patent/MY118164A/en
Priority to ZA9901077A priority patent/ZA991077B/xx
Priority to TW088102063A priority patent/TW518222B/zh
Priority to ARP990100598A priority patent/AR018286A1/es
Publication of FR2774591A1 publication Critical patent/FR2774591A1/fr
Application granted granted Critical
Publication of FR2774591B1 publication Critical patent/FR2774591B1/fr
Priority to NO20004056A priority patent/NO328314B1/no
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR9801709A 1998-02-12 1998-02-12 Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie Expired - Lifetime FR2774591B1 (fr)

Priority Applications (29)

Application Number Priority Date Filing Date Title
FR9801709A FR2774591B1 (fr) 1998-02-12 1998-02-12 Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
PCT/EP1999/000614 WO1999040904A2 (fr) 1998-02-12 1999-01-30 Composition pharmaceutique comprenant une combinaison de metformine et de fibrate, et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
CZ20002828A CZ290101B6 (cs) 1998-02-12 1999-01-30 Farmaceutický prostředek sestávající z kombinace metforminu a fibrátu a jeho použití k přípravě léčiv určených ke snižování hyperglykémie
EP99910169A EP1054665B1 (fr) 1998-02-12 1999-01-30 Composition pharmaceutique comprenant une combinaison de metformine et de fibrate, et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
HK01105732.1A HK1034913B (en) 1998-02-12 1999-01-30 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
PL342665A PL196874B1 (pl) 1998-02-12 1999-01-30 Preparat farmaceutyczny zawierający metforminę i fibrat oraz zastosowanie metforminy i fibratu do otrzymywania preparatu leczniczego do obniżania poziomu glukozy we krwi
SI9930017T SI1054665T1 (en) 1998-02-12 1999-01-30 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia
SK1156-2000A SK283212B6 (sk) 1998-02-12 1999-01-30 Farmaceutický prostriedok pozostávajúci z kombinácie metformínu a fibrátu a jeho použitie na znižovanie hyperglykémie
UA2000095172A UA70315C2 (en) 1998-02-12 1999-01-30 Pharmaceutical composition comprising metformin anpharmaceutical composition comprising metformin and fibrate useful for formulations intended for lowd fibrate useful for formulations intended for lowering hyperglycemia ering hyperglycemia
DE69900249T DE69900249T2 (de) 1998-02-12 1999-01-30 Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
PT81108560T PT1054665E (pt) 1998-02-12 1999-01-30 Composicao farmaceutica compreendendo uma combinacao de metformina e fibrato e seu uso no tratamento da hiperglicemia
HU0100801A HU224619B1 (hu) 1998-02-12 1999-01-30 Metformin és fibrát kombinációját tartalmazó gyógyászati készítmények és ezek alkalmazása kórosan magas vércukorszint csökkentését célzó gyógyszerek előállítására
DK99910169T DK1054665T3 (da) 1998-02-12 1999-01-30 Farmaceutisk præparat omfattende en kombination af metformin og fibrat og anvendelse deraf til fremstilling af medikamenter beregnet til at reducere hyperglykæmi
RU2000123567/14A RU2207850C2 (ru) 1998-02-12 1999-01-30 Фармацевтическая композиция, содержащая в комбинации метформин и фибрат, и ее применение при приготовлении лекарственных средств, предназначенных для снижения гипергликемии
BR9907866A BRPI9907866B8 (pt) 1998-02-12 1999-01-30 composição farmacêutica, bem como seu uso
US09/601,618 US6372790B1 (en) 1998-02-12 1999-01-30 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
ES99910169T ES2162517T3 (es) 1998-02-12 1999-01-30 Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia.
IDW20001765A ID26254A (id) 1998-02-12 1999-01-30 Komposisi farmasi yang terdiri dari satu gabungan antara metformin dan fibrate, dan penggunaannya dalam penyiapan obat-obatan yang ditujukan untuk menurukan hiperglikaemia
AU29233/99A AU746821B2 (en) 1998-02-12 1999-01-30 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
AT99910169T ATE204754T1 (de) 1998-02-12 1999-01-30 Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
CA002320039A CA2320039C (fr) 1998-02-12 1999-01-30 Composition pharmaceutique comprenant une combinaison de metformine et de fibrate, et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
KR1020007008836A KR100567608B1 (ko) 1998-02-12 1999-01-30 메트포르민과 피브레이트의 조합물로 이루어진 약학조성물, 및 과혈당증 저하용 약제의 제조 용도
CNB998029041A CN1151785C (zh) 1998-02-12 1999-01-30 含有二甲双胍和贝特联合的药物组合物及其在制备降低高血糖药物中的应用
JP2000531156A JP4767411B2 (ja) 1998-02-12 1999-01-30 メトホルミンおよびフィブラートとの組み合わせからなる医薬組成物と、高血糖症を緩和するための医薬品製造へのその使用
MYPI99000445A MY118164A (en) 1998-02-12 1999-02-09 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
ZA9901077A ZA991077B (en) 1998-02-12 1999-02-10 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia.
TW088102063A TW518222B (en) 1998-02-12 1999-02-10 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
ARP990100598A AR018286A1 (es) 1998-02-12 1999-02-12 Composicion farmaceutica que en calidad de principio activo contiene la asociacion de metformina y fibrato, y la utilizacion de esta asociacion para preparar medicamentos
NO20004056A NO328314B1 (no) 1998-02-12 2000-08-11 Farmasoytisk preparat som omfatter en kombinasjon av metformin og fibrat, og dets anvendelse til fremstilling av medisiner beregnet til a redusere hyperglykemi

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9801709A FR2774591B1 (fr) 1998-02-12 1998-02-12 Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie

Publications (2)

Publication Number Publication Date
FR2774591A1 FR2774591A1 (fr) 1999-08-13
FR2774591B1 true FR2774591B1 (fr) 2000-05-05

Family

ID=9522912

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9801709A Expired - Lifetime FR2774591B1 (fr) 1998-02-12 1998-02-12 Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie

Country Status (27)

Country Link
US (1) US6372790B1 (fr)
EP (1) EP1054665B1 (fr)
JP (1) JP4767411B2 (fr)
KR (1) KR100567608B1 (fr)
CN (1) CN1151785C (fr)
AR (1) AR018286A1 (fr)
AT (1) ATE204754T1 (fr)
AU (1) AU746821B2 (fr)
BR (1) BRPI9907866B8 (fr)
CA (1) CA2320039C (fr)
CZ (1) CZ290101B6 (fr)
DE (1) DE69900249T2 (fr)
DK (1) DK1054665T3 (fr)
ES (1) ES2162517T3 (fr)
FR (1) FR2774591B1 (fr)
HU (1) HU224619B1 (fr)
ID (1) ID26254A (fr)
MY (1) MY118164A (fr)
NO (1) NO328314B1 (fr)
PL (1) PL196874B1 (fr)
PT (1) PT1054665E (fr)
RU (1) RU2207850C2 (fr)
SK (1) SK283212B6 (fr)
TW (1) TW518222B (fr)
UA (1) UA70315C2 (fr)
WO (1) WO1999040904A2 (fr)
ZA (1) ZA991077B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE261935T1 (de) * 1997-12-08 2004-04-15 Bristol Myers Squibb Co Neue metformin salze und verfahren
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
FR2796940B1 (fr) * 1999-07-26 2005-04-08 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US7151191B2 (en) * 2000-01-13 2006-12-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
JP4829411B2 (ja) * 2001-02-23 2011-12-07 キッセイ薬品工業株式会社 Ｃ型慢性肝炎治療剤
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
WO2003105809A1 (fr) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Comprimes multicouche contenant des thiazolidinediones et des biguanides et procedes de production desdits comprimes
EP1424070A1 (fr) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combinaison d'un agoniste de PPAR-alpha et de metformine pour la réduction du taux de triglycérides sériques
BR0215979A (pt) 2002-12-13 2005-11-01 Jagotec Ag Formulação de espironolactona nanoparticulada tópica, uso de nanossuspensões de espironolactona, sistema de rede cristalina, e, processo para a preparação de uma formulação de espironolactona nanoparticulada tópica
BRPI0407303A (pt) * 2003-02-07 2006-02-07 Ajinomoto Kk Composição farmacêutica
FR2851734B1 (fr) * 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
RU2241449C1 (ru) * 2003-09-25 2004-12-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция для лечения диабета (варианты)
US8062664B2 (en) * 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
US7442720B2 (en) * 2003-12-19 2008-10-28 Omega Bio-Pharma (I.P.3) Limited Compositions and methods for treating diabetes
EP1559419A1 (fr) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Composition pharmaceutique contenant une combinaison de mefformine et d'un fibrate et les procédés pour les obtenir
US20070197602A1 (en) * 2004-02-09 2007-08-23 Hashime Kanazawa Combined pharmaceutical composition
EP1591114A1 (fr) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Utilisation de la metformine et de l'Orlistat pour le traitement ou la prévention de l'obésité
US20060286182A1 (en) * 2005-06-21 2006-12-21 Abeille Pharmaceuticals, Inc. Synergistic cinnamon combinations and methods for enhancing insulin activity
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
AU2006346853A1 (en) 2006-08-04 2008-02-07 Aska Pharmaceutical Co., Ltd. Drug formulation containing fibrate medicament and process for producing the same
CN101342164B (zh) * 2007-08-21 2011-04-20 阜新市仙鹤制药有限责任公司 苯扎贝特控释制剂及其制备方法
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
US9339458B2 (en) * 2009-02-18 2016-05-17 Itf Research Pharma, S.L.U. Use of vaginal insulin sensitizing agents
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
US9382187B2 (en) * 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8765811B2 (en) * 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
CN104684889A (zh) * 2012-07-10 2015-06-03 西蒂斯制药有限责任公司 二甲双胍的三盐形式
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
WO2015183794A1 (fr) 2014-05-27 2015-12-03 City Of Hope Complexes d'agonistes de tgr5 pour le traitement du diabète et du cancer
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
KR20170023061A (ko) 2014-06-18 2017-03-02 테티스 파마수티컬스 엘엘씨 활성제의 미네랄 아미노산 복합체
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
CA3026264A1 (fr) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions et procedes relatifs a des sels de mediateurs specialises de pro-resolution d'inflammation
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
WO2023119100A1 (fr) * 2021-12-22 2023-06-29 Mankind Pharma Ltd. Compositions pharmaceutiques stables

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2264525B1 (fr) * 1974-03-22 1977-11-04 Expl Marques Brevets Et
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
DE3729209A1 (de) * 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
ZA918168B (en) * 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
AU4050797A (en) * 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

Also Published As

Publication number Publication date
CZ290101B6 (cs) 2002-05-15
JP4767411B2 (ja) 2011-09-07
TW518222B (en) 2003-01-21
BRPI9907866B1 (pt) 2017-08-15
ATE204754T1 (de) 2001-09-15
NO20004056D0 (no) 2000-08-11
AU2923399A (en) 1999-08-30
CA2320039A1 (fr) 1999-08-19
CN1290160A (zh) 2001-04-04
KR100567608B1 (ko) 2006-04-04
HUP0100801A3 (en) 2001-12-28
PL196874B1 (pl) 2008-02-29
AU746821B2 (en) 2002-05-02
PT1054665E (pt) 2002-02-28
HK1034913A1 (en) 2001-11-09
NO328314B1 (no) 2010-01-25
DE69900249T2 (de) 2002-06-13
WO1999040904A2 (fr) 1999-08-19
MY118164A (en) 2004-09-30
ZA991077B (en) 1999-08-11
CN1151785C (zh) 2004-06-02
JP2002502869A (ja) 2002-01-29
SK11562000A3 (sk) 2000-12-11
UA70315C2 (en) 2004-10-15
WO1999040904A3 (fr) 1999-09-30
NO20004056L (no) 2000-08-11
BRPI9907866B8 (pt) 2021-05-25
AR018286A1 (es) 2001-11-14
RU2207850C2 (ru) 2003-07-10
FR2774591A1 (fr) 1999-08-13
BR9907866A (pt) 2000-10-31
CA2320039C (fr) 2008-07-22
KR20010040925A (ko) 2001-05-15
DK1054665T3 (da) 2001-12-27
EP1054665A2 (fr) 2000-11-29
ES2162517T3 (es) 2001-12-16
EP1054665B1 (fr) 2001-08-29
CZ20002828A3 (cs) 2000-11-15
SK283212B6 (sk) 2003-03-04
HUP0100801A2 (hu) 2001-08-28
US6372790B1 (en) 2002-04-16
HU224619B1 (hu) 2005-11-28
PL342665A1 (en) 2001-07-02
DE69900249D1 (de) 2001-10-04
ID26254A (id) 2000-12-07

Similar Documents

Publication Publication Date Title
FR2734483B1 (fr) Forme d'administration pharmaceutique comprenant de l'oxybutynine
FR11C0007I2 (fr) Composition pharmaceutique stabilisee a l'aide d'un agent de base
EP0788359A4 (fr) Compositions utiles a la preparation de medicaments destines au traitement de divers troubles refractaires
AU6379294A (en) Nasal pharmaceutical composition containing a progestational agent
HUS1200028I1 (hu) 4"-Szubsztituált-9-dezoxo-9a-aza-9a-homoeritromicin-származékok és ezeket tartalmazó gyógyszerek
ATE206924T1 (de) Oral anzuwendende arzneizubereitung enthaltend olanzapin
AU4344296A (en) Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor
FR2761265B1 (fr) Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
HUP9900605A3 (en) Lipopolyamines as transfection agents, preparation and use thereof and pharmaceutical compositions containing them
FR2732223B1 (fr) Composition pharmaceutique pour administration transdermique
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
ATE178489T1 (de) Fluessige oral anzuwendende arzneizubereitungen enthaltend paroxetinresinate
MA26507A1 (fr) Compositions pharmaceutiques d'aerosol
FI955691A7 (fi) Lipoproteiini(a):ta alentava aine, kolesterolia alentava aine ja näitä aineita sisältävät lääkkeet
HUP9900348A2 (hu) Új oxazolidinonszármazékok, előállításuk és alkalmazásuk, valamint ezeket a vegyületeket tartalmazó gyógyszerkészítmények
IL112745A0 (en) Formulations for orally administered pharmaceutical agents
FR2732217B1 (fr) Forme d'administration solide a usage oral
EE05317B1 (et) Etinl”stradiooli ja drospirenooni sisaldav farmatseutiline kompositsioon kasutamiseks rasestumisvastase vahendina
AU7001796A (en) Benzoic acid compounds and medicinal use thereof
FR2723317B1 (fr) Utilisation d'antagonistes de la neurotensine pour la preparation de medicaments diuretiques
AP9300559A0 (en) 3-and 5-substituted 1,2,3,4-oxatriazole-5-imine compounds,a process for the preparation thereof,a pharmaceutical preparation containing said compounds and the use of said compounds for the preparation of medicaments
FR2698544B1 (fr) Composition pharmaceutique topique pour allergies respiratoires.
EP0983763A4 (fr) Medicaments s'opposant a la reconstriction
IL116596A0 (en) 8-oxo-5, 8 dihydro-6h-dibenzo (a,g)quinolizine-13-propanoic acid derivatives their preparation and their therapeutic application
FR2746012B1 (fr) Utilisation de la tiamuline pour la preparation d'un medicament comme agent de reversion de la multichimioresistance cancereuse

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20